medigraphic.com
ISSN 1028-9933 (Electronic)

2019, Number 3

<< Back Next >>

RIC 2019; 98 (3)

Diagnostic, therapeutic and prognostic implications of the BRAF V600E mutation in cutaneous melanomas

Piamo MAJ

Language: Spanish
References: 27
Page: 413-424
PDF size: 752.25 Kb.


ABSTRACT

Introduction: Melanoma accounts for 4% of all malignant skin tumors, but is responsible for 80% of cancer deaths in this site. The emergence of therapies directed against the BRAF mutation has changed the prognosis, hence the importance of identifying this mutation in patients with histological diagnosis of malignant melanoma since the rate of mutations of the BRAF oncogene is high. Objective: to describe the diagnostic, therapeutic and prognostic implications of the determination of the mutation of the BRAF V600E gene in cutaneous malignant melanoma. Method: literature review via PUBMED with the introduction of the following search terms: melanoma, melanoma AND genetics, melanoma AND BRAF mutation, melanoma AND BRAF V600E AND prognosis. 72 publications were identified. Results: multiple studies have corroborated the high frequency of the mutated BRAF V600E oncogene in cutaneous melanoma, offering the possibility that through the identification of this alteration it can contribute to improve the diagnosis and to guarantee a treatment directed specifically against the activity of BRAF. Conclusions: the identification of the BRAF oncogene mutation represents a prognostic factor and may represent an effective therapeutic target.


REFERENCES

  1. Camacho Limas CP, Gerson Cwilich R, Góngora Jurado MA, Villalobos Prieto A, Blanco Vázquez YC, López Riverol O. Actualidades para el tratamiento del melanoma metastásico. An Med (Mex) [en línea] 2017 [citado 04/07/2019]; 62(3):196-207. Disponible en: https://www.medigraphic.com/pdfs/abc/bc-2017/bc173g.pdf [ Links ]

  2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. Cancer J Clin [en línea]. 2014 [citado 04/07/2019]; 64 (1): 9-29. DOI: 10.3322/caac.21208 [ Links ]

  3. Lavanderos FJ, Pérez PJ, Jeria NS, Concha CD. Actualizaciones en melanoma maligno cutáneo. Cuad Cir [en línea]. 2010 [citado 04/07/2019]; 24:47-56. Disponible en: http://mingaonline.uach.cl/pdf/cuadcir/v24n1/art08.pdf [ Links ]

  4. Telich Tarriba JE, Monter Plata A, Baldín AV, Apellaniz Campo A. Diagnóstico y tratamientode los tumores malignos de piel. Acta Méd Grupo Ángeles [en línea]. 2017 [citado 04/07/2019]; 15(2): 754-160. Disponible en: http://www.scielo.org.mx/pdf/amga/v15n2/1870-7203-amga-15-02-00154.pdf [ Links ]

  5. Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet [en línea]. 2014 [citado 04/07/2019]; 383(9919): 816-827. DOI: 10.1016/S0140-6736(13)60802-8 [ Links ]

  6. Bastian BC. The molecular pathology of melanoma: an integrated taxonomyof melanocytic neoplasia. Ann Rev Pathol [en línea]. 2014 [citado 04/07/2019]; 9:239-71. DOI: 10.1146/annurev-pathol-012513-104658 [ Links ]

  7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, et al. Mutations of the BRAF gene in human cancer. Nature [en línea] 2002 [citado 04/07/2019]; 417(6892):949-954. DOI: 10.1038/nature00766 [ Links ]

  8. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med [en línea]. 2010 [citado 04/07/2019]; 363(9):809-819. DOI: 10.1056/NEJMoa1002011 [ Links ]

  9. Ascierto PA, Kirkwood, Grob JJ, Simeone E, Grinaldi AM, Maio M, et al. The role of V600 mutation in melanoma. J transl Med [en línea]. 2012 [citado 04/07/2019]; 10:85. DOI: 10.1186/1479-5876-10-85 [ Links ]

  10. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H, et al. Distinct sets of genetic alterationsin melanoma. N Engl J Med [en línea]. 2005 [citado 04/07/2019]; 353:2135-2147. DOI: 10.1056/NEJMoa050092 [ Links ]

  11. Thomas NE, Edmiston SN, Alexander A, Millikan RC, Groben PA, Hao H, et al. Number of Nevi and Early-Life Ambient UV Exposure Are Associated with BRAF-Mutant Melanoma. Cancer Epidemiol Biom Prev [en línea]. 2007 [citado 04/07/2019]; 16(5):992-996. DOI: 10.1158/1055-9965.EPI-06-1038 [ Links ]

  12. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma. J Clin Oncol [en línea]. 2011 [citado 04/07/2019]; 29(10):1239-46. DOI: 10.1200/JCO.2010.32.4327 [ Links ]

  13. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenibin melanoma with BRAF V600E mutation. N Engl J Med [en línea]. 2011 [citado 04/07/2019]; 364(26):2507-16. DOI: 10.1056/NEJMoa1103782 [ Links ]

  14. Lemech C, Infante J, Arkenau HT. The Potential for BRAF V600 Inhibitors in Advanced Cutaneous Melanoma: Rationale and Latest Evidence. Ther Adv Med Oncol [en línea]. 2012 [citado 04/07/2019]; 4(2):61-73. DOI: 10.1177/1758834011432949 [ Links ]

  15. Lutz BS, Leguisamo NM, Cabral NK, Gloria HC, Reiter KC, Agnes G, et al. Imbalance in DNA repair machinery is associated with BRAFV600E mutation and tumor aggressiveness in papillary thyroid carcinoma. Mol Cell Endocrinol [en línea]. 2018 [citado 04/07/2019]; 472:140-148. DOI: 10.1016/j.mce.2017.12.004 [ Links ]

  16. Domínguez Ayala M, Expósito Rodríguez A, Bilbao González A, Mínguez Gabiña P, Gutiérrez Rodríguez T, Rodeño Ortiz de Zarate E, et al. Mutación del gen BRAF V600E en el cáncer papilar de tiroides y su efecto en la terapia con yodo radiactivo (131I) posquirúrgica: ¿deberíamos modificar nuestra estrategia terapéutica?. Cir Esp [en línea] 2018 [citado 04/07/2019]; 96(5):247-314. DOI: 10.1016/j.ciresp.2018.02.018 [ Links ]

  17. Oikonomou E, Makrodouli E, Evangelidou M, Joyce T, Probert L, Pintzas A. BRAFV600E efficient transformation and induction of microsatellite instability versus KRASG12V induction of senescence markers in human colon cáncer cells. Neoplasia. 2009; 11:1116-1131. [ Links ]

  18. Vakiani E, Solit DB. KRAS and BRAF: drug targets and predictive biomarkers. J Pathol [en línea] 2011 [citado 04/07/2019]; 223(2):219-229. DOI: 10.1002/path.2796 [ Links ]

  19. Grover R, Chana JS, Wilson GD, Richman PI, Sanders R. An analysis of p16 protein expression in sporadic malignant melanoma. Melanoma Res [en línea]. 1998 [citado 04/07/2019]; 8:267-72. Disponible en: https://europepmc.org/abstract/med/9664149 [ Links ]

  20. Reed JA, Loganzo F, Shea CR, Walker GJ, Flores JF, Glendening JM, et al. Loss of expression of the p16/cyclin dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stages of tumor progression. Cancer Res [en línea] 1995 [citado 04/07/2019]; 55:2713-2718. Disponible en: http://cancerres.aacrjournals.org/content/55/13/2713.full-text.pdf [ Links ]

  21. Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res [en línea]. 2012 [citado 04/07/2019]; 1:890-900. DOI: 10.1158/1078-0432.CCR-11-2246 [ Links ]

  22. Bringas A. Incidencia de la mutación del gen braf en pacientes con melanoma. Estudio bicéntrico en la ciudad de Córdoba. Argentina. [Tesis de Grado]. Argentina: Universidad Católica de Córdoba; 2014. Disponible en: http://pa.bibdigital.uccor.edu.ar/703/1/TRABAJO%20FINAL%20Melanoma.pdf [ Links ]

  23. Lin J, Goto Y, Murata H, Sakaizawa K, Uchiyama K Saida T, et al. Polyclonality of BRAF mutations in acquired melanocytic nevi. J Natl Cancer Inst [en línea]. 2009 [citado 04/07/2019]; 101(20):1423-7. DOI: 10.1093/jnci/djp309 [ Links ]

  24. Mazzei ME, Hochmann J, Manrique G, Mariño AL, Delgado L, Martínez Asuaga M. Determinación de la mutación BRAF V600E en melanomas de pacientes uruguayos. Rev Méd Urug [en línea]. 2013 [citado 04/07/2019]; 29(2):97-102. Disponible en: http://www.scielo.edu.uy/pdf/rmu/v29n2/v29n2a04.pdf [ Links ]

  25. Yépez Crow M. Correlación entre mutaciones en el exón 15 del oncogén BRAF con distintas características histopatológicas y la evolución clínica de pacientes con melanoma cutáneo en diferentes estadios. [tesis de Maestría]. Argentina: Universidad de Buenos Aires; 2015. Disponible en: http://repositoriouba.sisbi.uba.ar/gsdl/cgi-bin/library.cgi? [ Links ]

  26. Godoy Gijón E. Estudio de la mutación BRAF V600 en el melanoma cutáneo primario y metastásico. Correlación con variables clínicopatológicas. [Tesis doctoral]. Salamanca: Universidad de Salamanca; 2015. Disponible en: https://dialnet.unirioja.es/servlet/tesis?codigo=79814 [ Links ]

  27. Villanueva Álvarez-Santullan CA. Determinación de las mutaciones BRAF en melanomas primarios y Metastásicos. [Tesis Doctoral]. España: Universidad Complutense de Madrid; 2017. Disponible en: https://eprints.ucm.es/44696/ [ Links ]




2020     |     www.medigraphic.com